Management of extravasation of oxaliplatin by mimicking its biotransformation

Although oxaliplatin (Oxali) plays a key role in the treatment of many types of cancer and has been reported to be an irritant, there is no specific and effective method for its extravasation and failure in Oxali extravasation management results in the need for plastic surgery. In the body, Oxali bio-transforms upon dilution in chloride-containing buffer salts to its di-chloro derivative and loses an oxalate molecule. Consequently, the chloride ions exchange with water molecules in the intracellular environment to produce the di-aqua derivative, which is the most active biotransformation product of Oxali in terms of forming the DNA adducts. Thus, inhibiting transformation of di-chloro to di-aqua derivatives by accumulating chloride ions at the site of extravasation and saturating the Oxali molecule with these ions is a strategy that could help manage extravasation. Injecting normal saline at this site is a simple yet effective way to achieve this goal. © 2018, Federación de Sociedades Españolas de Oncología (FESEO).

  • Koleksiyonlar
Erişime Açık
Görüntülenme
10
22.03.2024 tarihinden bu yana
İndirme
1
22.03.2024 tarihinden bu yana
Son Erişim Tarihi
18 Mayıs 2024 13:34
Google Kontrol
Tıklayınız
Tam Metin
Tam Metin İndirmek için tıklayın Ön izleme
Detaylı Görünüm
Eser Adı
(dc.title)
Management of extravasation of oxaliplatin by mimicking its biotransformation
Yayın Türü
(dc.type)
Makale
Yazar/lar
(dc.contributor.author)
BAHADORI, Fatemeh
Yazar/lar
(dc.contributor.author)
DEMİRAY, Mutlu
DOI Numarası
(dc.identifier.doi)
10.1007/s12094-018-1854-z
Atıf Dizini
(dc.source.database)
Scopus
Konu Başlıkları
(dc.subject)
Biotransformation
Konu Başlıkları
(dc.subject)
Chemotherapy
Konu Başlıkları
(dc.subject)
Toxicity
Konu Başlıkları
(dc.subject)
Normal Saline
Konu Başlıkları
(dc.subject)
Oxaliplatin
Konu Başlıkları
(dc.subject)
Guideline
Konu Başlıkları
(dc.subject)
Extravasation
Konu Başlıkları
(dc.subject)
DNA Damage
Yayıncı
(dc.publisher)
Springer-Verlag Italia s.r.l.
Yayın Tarihi
(dc.date.issued)
2018
Kayıt Giriş Tarihi
(dc.date.accessioned)
2020-08-07T12:52:08Z
Açık Erişim tarihi
(dc.date.available)
2020-08-07T12:52:08Z
Kaynak
(dc.source)
Clinical and Translational Oncology
ISSN
(dc.identifier.issn)
1699048X (ISSN)
Özet
(dc.description.abstract)
Although oxaliplatin (Oxali) plays a key role in the treatment of many types of cancer and has been reported to be an irritant, there is no specific and effective method for its extravasation and failure in Oxali extravasation management results in the need for plastic surgery. In the body, Oxali bio-transforms upon dilution in chloride-containing buffer salts to its di-chloro derivative and loses an oxalate molecule. Consequently, the chloride ions exchange with water molecules in the intracellular environment to produce the di-aqua derivative, which is the most active biotransformation product of Oxali in terms of forming the DNA adducts. Thus, inhibiting transformation of di-chloro to di-aqua derivatives by accumulating chloride ions at the site of extravasation and saturating the Oxali molecule with these ions is a strategy that could help manage extravasation. Injecting normal saline at this site is a simple yet effective way to achieve this goal. © 2018, Federación de Sociedades Españolas de Oncología (FESEO).
Yayın Dili
(dc.language.iso)
en
Tek Biçim Adres
(dc.identifier.uri)
http://hdl.handle.net/20.500.12498/2842
Analizler
Yayın Görüntülenme
Yayın Görüntülenme
Erişilen ülkeler
Erişilen şehirler
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve cerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms